Regencell Bioscience Holdings Limited
RGC
$32.00
-$2.34-6.81%
NASDAQ
| 06/30/2024 | 03/31/2024 | 06/30/2023 | 12/31/2022 | 09/30/2022 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -28.23% | -28.23% | 8.31% | -18.25% | -18.25% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -14.75% | -14.75% | -28.15% | -6.27% | -6.27% |
| Operating Income | 14.75% | 14.75% | 28.15% | 6.27% | 6.27% |
| Income Before Tax | 20.74% | 20.74% | 30.20% | 9.39% | 9.39% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 20.74% | 20.74% | 30.20% | 9.39% | 9.39% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -155.90% | -155.90% | 27.34% | 30.27% | 30.27% |
| Net Income | 15.46% | 15.46% | 31.41% | 10.14% | 10.14% |
| EBIT | 14.75% | 14.75% | 28.15% | 6.27% | 6.27% |
| EBITDA | 15.78% | 17.72% | 30.54% | 7.99% | 7.99% |
| EPS Basic | 15.45% | 15.45% | 31.35% | 13.04% | 13.04% |
| Normalized Basic EPS | 5.37% | 5.37% | 26.99% | -- | -- |
| EPS Diluted | 15.45% | 15.45% | 31.35% | 13.04% | 13.04% |
| Normalized Diluted EPS | 5.37% | 5.37% | 26.99% | -- | -- |
| Average Basic Shares Outstanding | 0.00% | 0.00% | -0.07% | 3.36% | 3.36% |
| Average Diluted Shares Outstanding | 0.00% | 0.00% | -0.07% | 3.36% | 3.36% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |